Ultra-fast BCMA/CD70 CAR-T therapy for refractory lupus

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 1, investigator-initiated interventional study gives patients autologous CAR-T cells engineered to target BCMA and CD70, produced using an ultra-fast manufacturing system that can prepare cells in about 10 minutes. Eligible adults with active, refractory SLE will undergo leukapheresis, rapid CAR-T manufacturing, lymphodepletion as required, and a single CAR-T infusion with close safety monitoring. The primary focus is on safety and tolerability, with secondary measures including changes in SLEDAI-2K disease activity, steroid-sparing effects, and laboratory markers of B cell depletion. The study is conducted at a single center with short- and medium-term clinical and laboratory follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years old;
* Diagnosed with SLE according to the 2019 EULAR/ACR SLE classification criteria, and still in moderate to severe disease activity despite ≥3M of high dose glucocorticoids(prednisone≥1mg/kg/d or other equivalent amount of other steriod), and/or hydroxychloroquine, and at least 2 DMARDs(include cyclophosphamide, mycophenolate mofetil, azathioprine, methotrexate, cyclosporin, tacrolimus, sirolimus, leflunomide, telitacicept, beliumab, and rituximab) or intolerant to standard treatments;
* SLEDAI-2K score ≥ 8 points;
* Meet the standards of leukapheresis or intravenous blood collection, and no contraindication for leukapheresis;
* Negative pregnancy test for female subjects of childbearing age, and agree to take effective contraceptive measures until one year after CAR-T infusion;
* Participant or his/her guardians agree to participate in the clinical trial and sign the informed consent form which indicating that he/she understands the purpose and procedure of the clinical trial and is willing to participate in the study.

Exclusion Criteria:

* Central nervous system (CNS) disease: CNS neurolupus requires intervention within 30 days;
* Have a history of congenital heart disease or acute myocardial infarction within 6 months prior to screening or severe arrhythmias (including multisource frequent supraventricular tachycardia, ventricular tachycardia, etc.); or NYHA classification class IV; or combined with moderate to massive pericardial effusion, serious myocarditis, etc; or patient with unstable vital signs who need hypertensive drugs;
* The functions of important organs meet one of the following conditions: (1)renal function: eGFR\<30mL/min/1.73m2 or require renal replacement therapy; (2)liver function: AST and ALT\>3.0 ULN, total Bilirubin (TBIL) in serum \>2.0×ULN; (3)lung function: SpO2\<92% with no oxygen inhalation;
* Uncontrollable infection or active infection that requires systemic treatment within 3 months prior to screening;
* Received hematopoietic stem cell transplantation within 3 months prior to screening, or ≥Grade 2 GVHD within 2 weeks prior to screening;
* Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer greater than the normal reference value range; or hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA titer greater than the normal reference value range; or positive for human immunodeficiency virus (HIV) antibodies; or syphilis test positive;
* Suffered from active pulmonary tuberculosis at screening;
* Received live vaccine within 4 weeks prior to screening;
* Positive in blood pregnancy test;
* Suffered from malignant disease such as tumors (excluding tumors without active lesions and ending treatment for more than 5 years, as well as fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, thyroid cancer after radical resection, ductal carcinoma in situ after radical resection);
* Patients who participated in other clinical study within 3 months prior to screening;
* Any other conditions that the investigators deem it unsuitable for the study.

Where it's running

• Affiliated Drum Tower Hospital, Medical School of Nanjing University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Lingyun Sun
• Email: lingyunsun2012@163.com
• Phone: 13705186409

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• In vivo CAR-T therapy Arnovie101 for B cell–mediated autoimmune diseases

  This open-label, single-arm study tests Arnovie101, an mRNA-LNP-based in vivo CAR-T therapy, in adults with relapsed or refractory SLE or AIHA to see if it is safe and how the body handles it.

  Recruiting Early Phase 1 Circunited BioPharma (Shenzhen) Co., Ltd. · Beijing, Beijing Municipality · NCT07629596

• CD19 CAR-T (PTOC1) therapy for refractory systemic lupus erythematosus

  This study will try a fast-made CD19 CAR-T cell treatment called PTOC1 in people aged 5 and older whose lupus has not improved with high-dose steroids and multiple immunosuppressive drugs.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Chongqing · NCT07403097

• Ultra-fast autologous CD19 CAR-T therapy for refractory SLE

  This trial will try ultra-fast autologous CD19 CAR-T cells to see if they can control disease in adults with refractory systemic lupus erythematosus.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Nanjing, Jiangsu · NCT07331467

• Ultra-fast autologous CD19 CAR-T therapy for refractory systemic lupus erythematosus

  This trial will try ultra-fast autologous CD19 CAR-T cell therapy in people aged 5 and older with moderate-to-severe SLE that has not responded to high-dose steroids and multiple immunosuppressants.

  Recruiting Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07233642

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.